What is claimed is:

1. Use, as a catalyst for oxidation reactions, of at least one metal complex compound of formula (1)

$$[L_n Me_m X_p]^z Y_q$$
 (1),

wherein

Me is manganese, titanium, iron, cobalt, nickel or copper,

X is a coordinating or bridging radical,

n and m are each independently of the other an integer having a value of from 1 to 8, p is an integer having a value of from 0 to 32,

z is the charge of the metal complex,

Y is a counter-ion,

q = z/(charge of Y), and

L is a ligand of formula (2)

wherein

Q is N or CR₁₀,

R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉ and R₁₀ are each independently of the others hydrogen; unsubstituted or substituted C₁-C₁₈alkyl or unsubstituted or substituted aryl; cyano; halogen; nitro; -COOR₁₁ or -SO₃R₁₁ wherein

R₁₁ is in each case hydrogen, a cation or unsubstituted or substituted C₁-C₁₈alkyl or unsubstituted or substituted aryl; -SR₁₂, -SO₂R₁₂ or -OR₁₂ wherein

R₁₂ is in each case hydrogen or unsubstituted or substituted C₁-C₁₈alkyl or unsubstituted or substituted aryl; -NR₁₃R₁₄; -(C₁-C₆alkylene)-NR₁₃R₁₄; -N[®]R₁₃R₁₄R₁₅;

-(C₁-C₆alkylene)-N[®]R₁₃R₁₄R₁₅; -N(R₁₂)-(C₁-C₆alkylene)-NR₁₃R₁₄;

 $-N[(C_1-C_6alkylene)-NR_{13}R_{14}]_2; -N(R_{12})-(C_1-C_6alkylene)-N^{\theta}R_{13}R_{14}R_{15};$

PCT/EP2003/011636 WO 2004/039934

- 78 -

 $-N[(C_1-C_6a)] + N^6R_{13}R_{14}R_{15} = -N(R_{12}) - N-R_{13}R_{14}$ or $-N(R_{12}) - N^6R_{13}R_{14}R_{15}$, wherein R₁₂ is as defined above and

R₁₃, R₁₄ and R₁₅ are each independently of the other(s) hydrogen or unsubstituted or substituted C₁-C₁₈alkyl or unsubstituted or substituted aryl, or R₁₃ and R₁₄, together with the nitrogen atom linking them, form an unsubstituted or

substituted 5-, 6- or 7-membered ring which may contain further hetero atoms.

- 2. Use according to claim 1, wherein Me is manganese in the oxidation state II, III, IV or V.
- 3. Use according to claim 1, wherein Me is iron in the oxidation state II, III or IV.
- 4. Use according to any one of claims 1, 2 and 3, wherein X is CH₃CN, H₂O, F', Cl', Br', HOO', O₂², O², R₁₆COO', R₁₆O', LMeO' or LMeOO', wherein R₁₆ is hydrogen, -SO₃C₁-C₄alkyl or unsubstituted or substituted C₁-C₁₈alkyl or substituted or unsubstituted aryl, and L and Me are as defined in claim 1.
- 5. Use according to any one of claims 1 to 4, wherein Y is R₁₇COO, ClO₄, BF₄, PF₆, R₁₇SO₃, R₁₇SO₄, SO₄, NO₃, F, Cl, Br, I, citrate, tartrate or oxalate, wherein R₁₇ is hydrogen or unsubstituted or substituted C₁-C₁₈alkyl or substituted or unsubstituted aryl.
- 6. Use according to any one of claims 1 to 5, wherein n is an integer having a value of from 1 to 4, especially 1 or 2.
- 7. Use according to any one of claims 1 to 6, wherein m is an integer having a value of 1 or 2, especially 1.
- 8. Use according to any one of claims 1 to 7, wherein p is an integer having a value of from 0 to 4, especially 2.
- 9. Use according to any one of claims 1 to 8, wherein z is an integer having a value of from 8- to 8+.

WO 2004/039934 PCT/EP2003/011636

- 79 -

10. Use according to any one of claims 1 to 9, wherein aryl is phenyl or naphthyl each unsubstituted or substituted by C₁-C₄alkyl, C₁-C₄alkoxy, halogen, cyano, nitro, carboxy, sulfo, hydroxy, amino, N-mono- or N.N-di-C₁-C₄alkylamino unsubstituted or substituted by hydroxy in the alkyl moiety, N-phenylamino, N-naphthylamino, phenyl, phenoxy or by naphthyloxy.

11. Use according to any one of claims 1 to 10, wherein

the 5-, 6- or 7-membered ring formed by R_{13} and R_{14} together with the nitrogen atom linking them is an unsubstituted or C_1 - C_4 alkyl-substituted pyrrolidine, piperidine, piperazine, morpholine or azepane ring wherein the nitrogen atoms may be quaternised.

12. Use according to any one of claims 1 to 11, wherein

R₅ is C₁-C₁₂alkyl; phenyl unsubstituted or substituted by C₁-C₄alkyl, C₁-C₄alkoxy, halogen, cyano, nitro, carboxy, sulfo, hydroxy, amino, N-mono- or N,N-di-C₁-C₄alkylamino unsubstituted or substituted by hydroxy in the alkyl moiety, N-phenylamino, N-naphthylamino, phenyl, phenoxy or by naphthyloxy; cyano; halogen; nitro; -COOR11 or -SO3R11 wherein

R₁₁ is in each case hydrogen, a cation, C₁-C₁₂alkyl, unsubstituted phenyl or phenyl substituted as indicated above; -SR₁₂, -SO₂R₁₂ or -OR₁₂ wherein

R₁₂ is in each case hydrogen, C₁-C₁₂alkyl, unsubstituted phenyl or phenyl substituted as indicated above; $-NR_{13}R_{14}$; $-(C_1-C_6alkylene)-NR_{13}R_{14}$; $-N^{\oplus}R_{13}R_{14}R_{15}$;

 $-(C_1-C_6alkylene)-N^{\oplus}R_{13}R_{14}R_{15}$; $-N(R_{12})-(C_1-C_6alkylene)-NR_{13}R_{14}$ $N^{\theta}R_{13}R_{14}R_{15}$; $-N(R_{12})-N-R_{13}R_{14}$ or $-N(R_{12})-N^{\theta}R_{13}R_{14}R_{15}$, wherein

R₁₂ may have one of the above meanings and

R₁₃, R₁₄ and R₁₅ are each independently of the other(s) hydrogen, unsubstituted or hydroxysubstituted C₁-C₁₂alkyl, unsubstituted phenyl or phenyl substituted as indicated above, or R_{13} and R_{14} , together with the nitrogen atom linking them, form a pyrrolidine, piperidine, piperazine, morpholine or azepane ring unsubstituted or substituted by at least one unsubstituted C₁-C₄alkyl and/or substituted C₁-C₄alkyl, wherein the nitrogen atom may be quaternised, and R₁, R₂, R₃, R₄, R₆, R₇, R₈, R₉ and R₁₀ may be as defined in claim 1 or are hydrogen.

13. Use according to any one of claims 1 to 12, wherein

R₅ is phenyl unsubstituted or substituted by C₁-C₄alkvl, C₁-C₄alkoxy, halogen, phenyl or by hydroxy; cyano; nitro; -COOR₁₁ or -SO₃R₁₁ wherein

 R_{11} is in each case hydrogen, a cation, C_1 - C_4 alkyl or phenyl; -SR₁₂, -SO₂R₁₂ or -OR₁₂ wherein R₁₂ is in each case hydrogen, C_1 - C_4 alkyl or phenyl; -N(CH₃)-NH₂ or -NH-NH₂; amino; N-mono- or N,N-di- C_1 - C_4 alkylamino unsubstituted or substituted by hydroxy in the alkyl moiety; or an unsubstituted or C_1 - C_4 alkyl-substituted pyrrolidine, piperidine, piperazine, morpholine or azepane ring.

- 14. Use according to any one of claims 1 to 13, wherein
- R_5 in L is C_1 - C_4 alkoxy; hydroxy; hydroxy in the alkyl moiety; or an unsubstituted or C_1 - C_4 alkyl-substituted pyrrolidine, piperidine, piperazine, morpholine or azepane ring.
- 15. Use according to any one of claims 1 to 14, wherein R_1 , R_2 , R_3 , R_4 , R_6 , R_7 , R_8 , R_9 and R_{10} in L have the definitions given for R_5 in any one of claims 12 to 14, but those radicals may additionally be hydrogen.
- 16. Use according to any one of claims 1 to 15, wherein L is a compound of formula (3a) and/or (3b)

wherein R'₃, R'₅ and R'₇ have the definitions given in claims 1 to 15.

17. Use according to any one of claims 1 to 11, which comprises the use, as a catalyst for oxidation reactions, of at least one metal complex compound of formula (1')

$$[L'_nMe_mX_p]^2Y_q$$
 (1'),

wherein

Me is manganese, titanium, iron, cobalt, nickel or copper,

X is a coordinating or bridging radical,

n and m are each independently of the other an integer having a value of from 1 to 8,

p is an integer having a value of from 0 to 32,

z is the charge of the metal complex,

Y is a counter-ion,

q = z/(charge of Y), and

L' is a ligand of formula (2')

$$\begin{array}{c|c}
R_3 & R_4 & Q & B & N & R_6 \\
\hline
R_3 & A & N & N & C & R_7 \\
R_2 & R_1 & R_9 & R_8
\end{array}$$
(2')

wherein

Q is N or CR₁₀,

 R_1 , R_2 , R_3 , R_4 , R_5 , R_6 , R_7 , R_8 , R_9 and R_{10} are each independently of the others hydrogen; unsubstituted or substituted C_1 - C_{18} alkyl or unsubstituted or substituted aryl; cyano; halogen; nitro; -COOR₁₁ or -SO₃R₁₁ wherein

R₁₁ is in each case hydrogen, a cation or unsubstituted or substituted C₁-C₁₈alkyl or substituted or unsubstituted aryl; -SR₁₂, -SO₂R₁₂ or -OR₁₂ wherein

 R_{12} is in each case hydrogen or unsubstituted or substituted C_1 - C_{18} alkyl or unsubstituted or substituted aryl; -NR₁₃R₁₄; -(C_1 - C_6 alkylene)-NR₁₃R₁₄; -N[®]R₁₃R₁₄R₁₅;

 $-(C_1-C_6alkylene)-N^{\oplus}R_{13}R_{14}R_{15};-N(R_{12})-(C_1-C_6alkylene)-NR_{13}R_{14};-N[(C_1-C_6alkylene)-NR_{13}R_{14}]_2;$

 $-N(R_{12})-(C_1-C_6alkylene)-N^{\oplus}R_{13}R_{14}R_{15};-N[(C_1-C_6alkylene)-N^{\oplus}R_{13}R_{14}R_{15}]_2;-N(R_{12})-N-R_{13}R_{14}$ or

-N(R₁₂)-N[®]R₁₃R₁₄R₁₅, wherein

R₁₂ is as defined above and

R₁₃, R₁₄ and R₁₅ are each independently of the other(s) hydrogen or unsubstituted or substituted C₁-C₁₈alkyl or unsubstituted or substituted aryl, or

 R_{13} and R_{14} , together with the nitrogen atom linking them, form an unsubstituted or substituted 5-, 6- or 7-membered ring which may contain further hetero atoms, with the proviso that

at least one of the substituents R_1 to R_{10} contains a quaternised nitrogen atom that is not bonded directly to one of the three rings A, B and/or C.

18. Use according to claim 17, wherein R₅ is not hydrogen.

WO 2004/039934 PCT/EP2003/011636

- 82 -

19. Use according to either claim 17 or claim 18, wherein

 R_5 in L' is phenyl unsubstituted or substituted by C_1 - C_4 alkyl, C_1 - C_4 alkoxy, halogen, phenyl or by hydroxy; cyano; nitro; -COOR₁₁ or -SO₃R₁₁ wherein

 R_{11} is in each case hydrogen, a cation, C_1 - C_4 alkyl or phenyl; -SR₁₂, -SO₂R₁₂ or -OR₁₂ wherein R₁₂ is in each case hydrogen, C_1 - C_{14} alkyl or phenyl; -N(CH₃)-NH₂ or -NH-NH₂; amino; N-mono- or N,N-di- C_1 - C_4 alkylamino unsubstituted or substituted by hydroxy in the alkyl moiety, wherein the nitrogen atoms, especially the nitrogen atoms not bonded to one of the three rings A, B or C, may be quaternised; N-mono- or N,N-di- C_1 - C_4 alkyl-N[®]R₁₃R₁₄R₁₅ unsubstituted or substituted by hydroxy in the alkyl moiety, wherein

 R_{13} , R_{14} and R_{15} are each independently of the others hydrogen or unsubstituted or hydroxy-substituted C_1 - C_{12} alkyl, unsubstituted phenyl or phenyl substituted as indicated above, or R_{13} and R_{14} , together with the nitrogen atom linking them, form a pyrrolidine, piperidine, piperazine, morpholine or azepane ring unsubstituted or substituted by at least one C_1 - C_4 alkyl or by at least one unsubstituted C_1 - C_4 alkyl and/or substituted C_1 - C_4 alkyl, wherein the nitrogen atom may be quaternised; N-mono- or N,N-di- C_1 - C_4 alkyl-NR₁₃R₁₄ unsubstituted or substituted by hydroxy in the alkyl moiety, wherein R_{13} and R_{14} may be as defined above.

20. Use according to any one of claims 17 to 19, wherein L' is a compound of formula (3'a) and/or (3'b)

wherein R'₃, R'₅ and R'₇ have the definitions and preferred meanings indicated above for R₅, but R'₃ and R'₇ may additionally be hydrogen.

- 21. Use according to any one of claims 17 to 20, wherein
- (i) at least one of the substituents R'₃, R'₅ and R'₇ is one of the radicals

WO 2004/039934 PCT/EP2003/011636

$$-C_1\text{-}C_4\text{alkylene}-\text{N} \\ \text{V} \\ C_1\text{-}C_4\text{alkyl} \\ \text{or} \\ \text{-} \\ \text{N} \\ \text{C}_1\text{-}C_4\text{alkyl} \\ \text{or} \\ \text{-} \\ \text{N} \\ \text{-} \\ \text{C}_1\text{-}\\ \text{C}_4\text{alkyl} \\ \text{-} \\ \text{-} \\ \text{N} \\ \text{-} \\$$

wherein the unbranched or branched alkylene group may be unsubstituted or substituted, and wherein the alkyl groups, which are unbranched or branched independently of one another, may be unsubstituted or substituted and wherein the piperazine ring may be unsubstituted or substituted.

- 22. Use according to any one of claims 17 to 21, wherein L' contains precisely 1 quatemised nitrogen atom.
- 23. Use according to any one of claims 17 to 22, wherein L' contains precisely 2 or precisely 3 quaternised nitrogen atoms.
- 24. Use according to any one of claims 1 to 23, wherein the oxidation is carried out using molecular oxygen and/or air.
- 25. A metal complex compound of formula (1a)

$$[L_n Me_m X_p]^z Y_q$$
 (1a),

wherein all substituents are as defined in any one of claims 1 to 16.

26. A metal complex compound of formula (1a) according to claim 25, wherein L is a compound of formula (3a) and/or (3b)

wherein

R'₅ is C₁-C₄alkoxy; hydroxy; N-mono- or N,N-di-C₁-C₄alkylamino substituted by hydroxy in the alkyl moiety; or -NR₁₃R₁₄; -(C₁-C₆alkylene)-NR₁₃R₁₄;

WO 2004/039934 PCT/EP2003/011636

- 84 -

 $-N(R_{12})-(C_1-C_6alkylene)-NR_{13}R_{14}; -N[(C_1-C_6alkylene)-NR_{13}R_{14}]_2;$ or -N(R₁₂)-N-R₁₃R₁₄, wherein

R₁₂ is hydrogen; C₁-C₁₂alkyl or unsubstituted phenyl or phenyl substituted by (substituted in the alkyl moiety by hydroxy) N-mono- or

N,N-di-C₁-C₄alkylamino-, N-phenylamino-, N-naphthylamino-, phenyl-, phenoxy- or naphthyloxy, and

R₁₃ and R₁₄ are each independently of the other hydrogen, unsubstituted or hydroxy-substituted C₁-C₁₂alkyl, unsubstituted phenyl or phenyl substituted as indicated above, or

R₁₃ and R₁₄, together with the nitrogen atom linking them, form a pyrrolidine, piperidine, piperazine, morpholine or azepane ring that is unsubstituted or substituted by at least one unsubstituted C1-C4alkyl and/or substituted C1-C₄alkyl, especially a pyrrolidine, piperidine, piperazine, morpholine or azepane ring, and

R'₃ and R'₇ are each independently of the other hydrogen; C₁-C₄alkoxy; hydroxy; N-monoor N,N-di-C₁-C₄alkylamino substituted by hydroxy in the alkyl moiety; or -NR₁₃R₁₄; -(C₁-C₆alkylene)-NR₁₃R₁₄; -N(R₁₂)-(C₁-C₆alkylene)-NR₁₃R₁₄;

 $-N[(C_1-C_6alkylene)-NR_{13}R_{14}]_2$; or $-N(R_{12})-N-R_{13}R_{14}$, wherein

R₁₂ is hydrogen; C₁-C₁₂alkyl or unsubstituted or (substituted in the alkyl moiety by hydroxy) N-mono- or N,N-di-C₁-C₄alkylamino-, N-phenylamino-, N-naphthylamino-, phenyl-, phenoxy- or naphthyloxy-substituted phenyl, and

R₁₃ and R₁₄ are each independently of the other hydrogen; unsubstituted or hydroxy-substituted C₁-C₁₂alkyl, unsubstituted phenyl or phenyl substituted as indicated above, or

R₁₃ and R₁₄, together with the nitrogen atom linking them, form a pyrrolidine, piperidine, piperazine, morpholine or azepane ring that is unsubstituted or substituted by at least one unsubstituted C₁-C₄alkyl and/or substituted C₁-C₄alkyl, especially a pyrrolidine, piperazine, morpholine or azepane ring.

27. A metal complex compound of formula (1'a)

 $[L'_nMe_mX_n]^2Y_a$ (1'a).

wherein all substituents are as defined in claims 17 to 23.

28. A metal complex compound of formula (1'a) according to claim 27, wherein L' is a compound of formula (3'a) and/or (3'b)

wherein R'_3 , R'_5 and R'_7 have the definitions and preferred meanings given above for R_5 in claims 17 to 23, but R'_3 and R'_7 may additionally be hydrogen, with the proviso that

(i) at least one of the substituents R'3, R'5 and R'7 is a radical

 $-(C_1-C_6alkylene)-N^{\oplus}R_{13}R_{14}R_{15}; -N(R_{12})-(C_1-C_6alkylene)-N^{\oplus}R_{13}R_{14}R_{15};$

 $-N[(C_1-C_6alkylene)-N^{\oplus}R_{13}R_{14}R_{15}]_2; -N(R_{12})-N^{\oplus}R_{13}R_{14}R_{15}, wherein$

R₁₂ is as defined above and

 R_{13} , R_{14} and R_{15} are each independently of the others hydrogen or unsubstituted or substituted C_1 - C_{18} alkyl or substituted or unsubstituted aryl, or

R₁₃ and R₁₄, together with the nitrogen atom linking them, form an unsubstituted or substituted 5-, 6- or 7-membered ring which may contain further hetero atoms; or

 $-NR_{13}R_{14}$; $-(C_1-C_6alkylene)-NR_{13}R_{14}$; $-N(R_{12})-(C_1-C_6alkylene)-NR_{13}R_{14}$;

 $-N[(C_1-C_6alkylene)-NR_{13}R_{14}]_2$; $-N(R_{12})-N-R_{13}R_{14}$, wherein

R₁₂ and R₁₅ are as defined above and R₁₃ and R₁₄, together with the nitrogen atom linking them, form a 5-, 6- or 7-membered ring which may be unsubstituted or substituted by at least one unsubstituted C₁-C₄alkyl and/or substituted C₁-C₄alkyl and may contain further hetero atoms, wherein at least one nitrogen atom not bonded to one of the rings A, B and/or C is quaternised.

29. A ligand L' according to any one of claims 17 to 23, 27 and 28 of formula (4') or (5')

WO 2004/039934 PCT/EP2003/011636

- 86 -

wherein

R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉ and R₁₀ are each independently of the others hydrogen; unsubstituted or substituted C₁-C₁₈alkyl or substituted or unsubstituted aryl; cyano; halogen; nitro; -COOR₁₁ or -SO₃R₁₁ wherein

R₁₁ is in each case hydrogen, a cation or unsubstituted or substituted C₁-C₁₈alkyl or substituted or unsubstituted aryl; -SR₁₂, -SO₂R₁₂ or -OR₁₂ wherein

R₁₂ is in each case hydrogen or unsubstituted or substituted C₁-C₁₈alkyl or substituted or unsubstituted aryl; -NR₁₃R₁₄; -(C₁-C₆alkylene)-NR₁₃R₁₄;

 $-N^{\oplus}R_{13}R_{14}R_{15}$; $-(C_1-C_6alkylene)-N^{\oplus}R_{13}R_{14}R_{15}$; $-N(R_{12})-(C_1-C_6alkylene)-NR_{13}R_{14}$;

 $-N[(C_1-C_6alkylene)-NR_{13}R_{14}]_2; -N(R_{12})-(C_1-C_6alkylene)-N^{\oplus}R_{13}R_{14}R_{15};$

 $-N[(C_1-C_6alkylene)-N^{\oplus}R_{13}R_{14}R_{15}]_2; -N(R_{12})-N-R_{13}R_{14} \text{ or } -N(R_{12})-N^{\oplus}R_{13}R_{14}R_{15}, \text{ wherein } -N(R_{12})-N-R_{13}R_{14}R_{15}]_2; -N(R_{12})-N-R_{13}R_{14} \text{ or } -N(R_{12})-N^{\oplus}R_{13}R_{14}R_{15}$ R₁₂ is as defined above and

R₁₃, R₁₄ and R₁₅ are each independently of the other(s) hydrogen or unsubstituted or substituted C₁-C₁₈alkyl or substituted or unsubstituted aryl, or

R₁₃ and R₁₄, together with the nitrogen atom linking them, form an unsubstituted or substituted 5-, 6- or 7-membered ring which may contain further hetero atoms, with the proviso that

at least one of the substituents R₁ to R₁₀ contains a quaternised nitrogen atom that is not bonded directly to one of the three rings A, B and/or C.

30. A ligand L according to any one of claims 1 to 16, 25 and 26 of formula (6)

$$\begin{array}{c|cccc}
R_3 & R_4 & N & B & R_6 & R_7 \\
R_2 & R_1 & N & R_8 & R_8
\end{array}$$
(6)

wherein

R₁, R₂, R₄, R₅, R₆, R₇, R₈ and R₉ are each independently of the others hydrogen; unsubstituted or substituted C₁-C₁₈alkyl or substituted or unsubstituted aryl; cyano; halogen; nitro; -COOR₁₁ or -SO₃R₁₁ wherein

R₁₁ is in each case hydrogen, a cation or unsubstituted or substituted C₁-C₁₈alkyl or substituted or unsubstituted aryl; -SR₁₂, -SO₂R₁₂ or -OR₁₂ wherein

 R_{12} is in each case hydrogen or unsubstituted or substituted C_1 - C_{18} alkyl or substituted or unsubstituted aryl; -NR₁₃R₁₄; -(C_1 - C_6 alkylene)-NR₁₃R₁₄;

- $-N^{\oplus}R_{13}R_{14}R_{15}$; $-(C_1-C_6alkylene)-N^{\oplus}R_{13}R_{14}R_{15}$; $-N(R_{12})-(C_1-C_6alkylene)-NR_{13}R_{14}$;
- $-N[(C_1-C_6alkylene)-NR_{13}R_{14}]_2; -N(R_{12})-(C_1-C_6alkylene)-N^{\oplus}R_{13}R_{14}R_{15};$
- $-N[(C_1-C_6alkylene)-N^{\oplus}R_{13}R_{14}R_{15}]_2$; $-N(R_{12})-N-R_{13}R_{14}$; or $-N(R_{12})-N^{\oplus}R_{13}R_{14}R_{15}$, wherein R_{12} is as defined above and

R₁₃, R₁₄ and R₁₅ are each independently of the other(s) hydrogen or unsubstituted or substituted C₁-C₁₈alkyl or substituted or unsubstituted anyl, or

R₁₃ and R₁₄, together with the nitrogen atom linking them, form an unsubstituted or substituted 5-, 6- or 7-membered ring which may contain further hetero atoms, and

 R_3 is phenyl substituted by C_1 - C_4 alkyl, C_1 - C_4 alkoxy, hydroxy, sulfo, sulfato, halogen, cyano, nitro, carboxy, amino, N-mono- or N,N-di- C_1 - C_4 alkylamino unsubstituted or substituted by hydroxy in the alkyl moiety, N-phenylamino, N-naphthylamino, phenyl, phenoxy or by naphthyloxy, substituted C_1 - C_{18} alkyl or substituted or unsubstituted aryl; - CH_3 ; C_3 - C_{18} alkyl; cyano; halogen; nitro; - $COOR_{11}$ or - SO_3R_{11} wherein

R₁₁ is in each case hydrogen, a cation or unsubstituted or substituted C₁-C₁₈alkyl or substituted or unsubstituted aryl; -SR₁₂, -SO₂R₁₂ or -OR₁₂ wherein

 R_{12} is in each case hydrogen or unsubstituted or substituted C_1 - C_{18} alkyl or substituted or unsubstituted aryl; - $NR_{13}R_{14}$; - $(C_1$ - C_6 alkylene)- $NR_{13}R_{14}$; - $N^{\oplus}R_{13}R_{14}R_{15}$;

- $-(C_1-C_6alkylene)-N^{\oplus}R_{13}R_{14}R_{15}; -N(R_{12})-(C_1-C_6alkylene)-NR_{13}R_{14};$
- $-N[(C_1-C_6alkylene)-NR_{13}R_{14}]_2; -N(R_{12})-(C_1-C_6alkylene)-N^{\oplus}R_{13}R_{14}R_{15};$
- -N[(C₁-C₆alkylene)-N[®]R₁₃R₁₄R₁₅]₂; -N(R₁₂)-N-R₁₃R₁₄; or –N(R₁₂)-N[®]R₁₃R₁₄R₁₅, wherein R₁₂ is as defined above and

R₁₃, R₁₄ and R₁₅ are each independently of the other(s) hydrogen or unsubstituted or substituted C₁-C₁₈alkyl or substituted or unsubstituted aryl, or

R₁₃ and R₁₄, together with the nitrogen atom linking them, form an unsubstituted or substituted 5-, 6- or 7-membered ring which may contain further hetero atoms.

- 88 -

31. A ligand L according to any one of claims 1 to 16, 25 and 26 of formula (7)

$$\begin{array}{c|c}
R_{10} & R_{5} \\
R_{4} & B & R_{6} \\
R_{2} & R_{1} & R_{9} \\
\end{array}$$

$$\begin{array}{c|c}
R_{10} & R_{5} \\
R_{10} & R_{10} \\
R_{20} & R_{10} \\
R_{20} & R_{20} \\
R_{10} & R_{20} \\
R_{20} & R_{20} \\
R$$

wherein

R₁, R₂, R₃, R₄, R₅, R₆, R₈, R₉ and R₁₀ are each independently of the others hydrogen; unsubstituted or substituted C₁-C₁₈alkyl or substituted or unsubstituted aryl; cyano; halogen; nitro; -COOR₁₁ or -SO₃R₁₁ wherein

R₁₁ is in each case hydrogen, a cation or unsubstituted or substituted C₁-C₁₈alkyl or substituted or unsubstituted aryl; -SR₁₂, -SO₂R₁₂ or -OR₁₂ wherein

R₁₂ is in each case hydrogen or unsubstituted or substituted C₁-C₁₈alkyl or unsubstituted or substituted substituted or unsubstituted aryl; -NR₁₃R₁₄; -(C₁-C₆alkylene)-NR₁₃R₁₄;

 $-N^{\oplus}R_{13}R_{14}R_{15}$; $-(C_1-C_6a)kylene$ $-N^{\oplus}R_{13}R_{14}R_{15}$; $-N(R_{12})-(C_1-C_6a)kylene$ $-NR_{13}R_{14}$;

 $-N[(C_1-C_6alkylene)-NR_{13}R_{14}]_2; -N(R_{12})-(C_1-C_6alkylene)-N^{\oplus}R_{13}R_{14}R_{15};$

 $-N[(C_1-C_6a)] + N^{\oplus}R_{13}R_{14}R_{15}]_2$; $-N(R_{12})-N-R_{13}R_{14}$ or $-N(R_{12})-N^{\oplus}R_{13}R_{14}R_{15}$, wherein R₁₂ is as defined above and

R₁₃, R₁₄ and R₁₅ are each independently of the other(s) hydrogen or unsubstituted or substituted C₁-C₁₈alkyl or substituted or unsubstituted aryl, or

R₁₃ and R₁₄, together with the nitrogen atom linking them, form an unsubstituted or substituted 5-, 6- or 7-membered ring which may contain further hetero atoms, and

R₇ is phenyl substituted by C₁-C₄alkyl, C₁-C₄alkoxy, hydroxy, sulfo, sulfato, halogen, cyano, nitro, carboxy, amino, N-mono- or N,N-di-C₁-C₄alkylamino unsubstituted or substituted by hydroxy in the alkyl moiety, N-phenylamino, N-naphthylamino, phenyl, phenoxy or by naphthyloxy, substituted C₁-C₁₈alkyl or substituted or unsubstituted aryl; -CH₃: C₃-C₁₈alkyl; cyano; F; Br; I; nitro; -COOR₁₁ or -SO₃R₁₁ wherein

R₁₁ is in each case hydrogen, a cation or unsubstituted or substituted C₁-C₁₈alkyl or substituted or unsubstituted aryl; -SR₁₂, -SO₂R₁₂ or -OR₁₂ wherein

R₁₂ is in each case hydrogen or unsubstituted or substituted C₁-C_{1e}alkyl or unsubstituted or substituted aryl; -NR₁₃R₁₄; -(C₁-C₆alkylene)-NR₁₃R₁₄; -N^{θ}R₁₃R₁₄R₁₅;

 $-(C_1-C_6alkylene)-N^{\oplus}R_{13}R_{14}R_{15}$; $-N(R_{12})-(C_1-C_6alkylene)-NR_{13}R_{14}$;

- $-N[(C_1-C_6a)] + NR_{13}R_{14}]_2; -N(R_{12}) (C_1-C_6a) + N^{\theta}R_{13}R_{14}R_{15};$
- $-N[(C_1-C_6alkylene)-N^{\oplus}R_{13}R_{14}R_{15}]_2$; $-N(R_{12})-N-R_{13}R_{14}$; or $-N(R_{12})-N^{\oplus}R_{13}R_{14}R_{15}$, wherein R₁₂ is as defined above and

R₁₃, R₁₄ and R₁₅ are each independently of the other(s) hydrogen or unsubstituted or substituted C₁-C₁₈alkyl or substituted or unsubstituted aryl, or

R₁₃ and R₁₄, together with the nitrogen atom linking them, form an unsubstituted or substituted 5-, 6- or 7-membered ring which may contain further hetero atoms.

- A detergent, cleaning, disinfecting or bleaching composition containing
 - I) from 0 to 50% A) of an anionic surfactant and/or B) of a non-ionic surfactant,
 - II) from 0 to 70% C) of a builder substance,
 - III) from 1 to 99% D) of a peroxide,
 - IV) E) at least one metal complex compound of formula (1) and/or (1') of any one of claims 25 to 28 in an amount that, in the liquor, gives a concentration of from 0.5 to 50 mg/litre of liquor, preferably from 1 to 30 mg/litre of liquor, when from 0.5 to 20 g/litre of the detergent, cleaning, disinfecting or bleaching agent are added to the liquor, the percentages in each case being percentages by weight, based on the total weight of the composition, and
 - V) water ad 100%.

33. A solid formulation containing

- a) from 1 to 99% by weight of a metal complex compound of formula (1) and/or (1') of any one of claims 25 to 28,
- b) from 1 to 99% by weight of a binder,
- c) from 0 to 20% by weight of an encapsulating material,
- d) from 0 to 20% by weight of a further additive and
- e) from 0 to 20% by weight of water.
- 34. A solid formulation according to claim 33, which is in the form of tablets or granules.